US Patent

US9694008 — Fast-dissolving oral film preparation comprising aripiprazole

Formulation · Assigned to CMG Pharmaceutical Co Ltd · Expires 2033-08-07 · 7y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a fast-dissolving oral film formulation containing aripiprazole, an active ingredient in the drug Abilify.

USPTO Abstract

The present invention relates to an orally fast dissolving film formulation including aripiprazole. The orally fast dissolving film formulation includes aripiprazole or a pharmaceutically acceptable salt thereof and an organic acid. The orally fast dissolving film formulation has a pH in the range of 4.7 to 6.0. The orally fast dissolving film formulation may further include a film base polymer. The orally fast dissolving film formulation has a high dissolution rate, causes no risk of damage to oral tissues, masks a bitter taste of aripiprazole, and gives a good feeling upon taking.

Drugs covered by this patent

Patent Metadata

Patent number
US9694008
Jurisdiction
US
Classification
Formulation
Expires
2033-08-07
Drug substance claim
No
Drug product claim
Yes
Assignee
CMG Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.